---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-073709"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:20:33.876698+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Intellia appoints Brian Goff to board; former Alexion commercial executive

## Summary
- Appointed as Class I director effective June 13, 2024; term through 2026 annual meeting.
- Goff is CEO of Agios Pharmaceuticals; over 30 years biopharma commercial experience including EVP at Alexion.
- Received option for 22,297 shares at $25.96 and 15,409 RSUs, vesting over three years.
- Appointed to Compensation and Talent Development Committee; independent under Nasdaq rules.

## SEC filing metadata
- accession: 0000950170-24-073709
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000095017024073709/0000950170-24-073709-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000095017024073709/ntla-20240612.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-073709
- JSON: https://secwatch.observer/filing/0000950170-24-073709.json
- Plain text: https://secwatch.observer/filing/0000950170-24-073709.txt

## Key facts
- Executive change
  Brian Goff was appointed as Class I Director at Intellia Therapeutics, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: On June 12, 2024, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Intellia Therapeutics, Inc. (the “Company”), the Board appointed Brian Goff, as a Class I director, effective as of June 13, 2024, with a term expiring at the 2026 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000095017024073709/0000950170-24-073709-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.